Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - March 2017

Recent News

Mar. 01, 2017Juno Therapeutics Reports Fourth Quarter and 2016 Financial ResultsPrinter Friendly Version
Feb. 28, 2017Juno Therapeutics to Present at March 2017 Investor ConferencesPrinter Friendly Version
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development OperationsPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

03/16/17 10:45 a.m. ET
Juno Therapeutics at 2017 Barclays Global Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources